Drug Type Bispecific T-cell Engager (BiTE) |
Synonyms Anti-Claudin-6 mAb (Integral Molecular) |
Target |
Action stimulants, inhibitors |
Mechanism CD3 stimulants(T cell surface glycoprotein CD3 stimulants), CLDN6 inhibitors(Claudin 6 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Ovarian Cancer | Phase 1 | United States | 30 May 2018 | |
Endometrioid Carcinoma | Preclinical | United States | 23 Mar 2022 |